Yazar "Yilmaz, N." için listeleme
-
COULD SERUM TWEAK LEVEL BE AN INDICATOR OF SUBCLINICAL ATHEROSCLEROSIS IN RHEUMATOID ARTHRITIS?
Ucer, M.; Yilmaz, N.; Elcioglu, B. Cengiz; Sahin, T.; Atak, P. Gun; Yavuz, S. (BMJ PUBLISHING GROUP, 2017)… -
INCIDENCE OF ANTERIOR UVEITIS IN AXIAL SPONDYLOARTHRITIS DURING SECUKINUMAB TREATMENT: TWO YEARS REAL LIFE EXPERIENCE FROM TURKBIO REGISTRY
Akleylek, C.; Akar, S.; Cinakli, H.; Sagir, R. Piskin; Coskun, B. N.; Karakas, A.; Yilmaz, N. (Bmj Publishing Group, 2022)[No Abstract Available] -
INCREASED EPICARDIAL ADIPOSE TISSUE IN PATIENTS WITH SYSTEMIC SCLEROSIS
Yilmaz, N.; Baysal, E.; Karadag, O. (BMJ PUBLISHING GROUP, 2014)… -
Increased Oxidative Stress and Imbalance Dynamic Thiol–Disulfide Homeostasis in Rosacea
Guler, E.M.; Ozkan, B.N.; Yilmaz, N.; Ozgen, F.P.; Taslidere, N.S.; Aktas, S.; Kucuk, O.S. (Galenos Publishing House, 2022)Background: Rosacea is a chronic progressive inflammatory disease and characterized by facial erythema, telangiectasias, papules, and pustules. The disease is more common in women than in men while affecting 2%–10% of the ... -
Malignancy risk in systemic Lupus Erythematosus patients treated with cyclophosphamide
Yilmaz, N.; Emmungil, H.; Gucenmez, S.; Ozen, G.; Yildiz, F.; Balkarli, A.; Yavuz, S. (CLINICAL & EXPER RHEUMATOLOGY, 2015)… -
PREGNANCY OUTCOME IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Pamuk, O. N.; BAlci, M. A.; Yilmaz, N.; Yavuz, S. (BMJ PUBLISHING GROUP, 2016)… -
Risk factors for malignancy in systemic sclerosis patients
Kasifoglu, T.; Bilge, S. Yasar; Yildiz, F.; Ozen, G.; Pehlivan, Y.; Yilmaz, N.; Onat, A. M. (SPRINGER LONDON LTD, 2016)Systemic sclerosis (SSc) is an autoimmune connective tissue disease with multisystem involvement. An increased incidence of cancer in SSc patients compared with the general population has been reported in several reports. ...
